094 - Checkpoint Therapeutics Targets MASSIVE Solid Tumor Market | Interview with CEO James Oliviero

Поділитися
Вставка
  • Опубліковано 15 гру 2024

КОМЕНТАРІ • 12

  • @troy8735
    @troy8735 2 роки тому +2

    Update results were great! Next step approval. 🤞

  • @sauss4472
    @sauss4472 11 годин тому

    Fda Approved 🎉

  • @PutyLink-c1g
    @PutyLink-c1g Місяць тому

    It is now time to boom! 28.dec.2024 watch out CKPT!

  • @marcusw9894
    @marcusw9894 3 роки тому +6

    Very promising company. Lots of potential.

  • @danielrd7493
    @danielrd7493 3 роки тому +5

    I hope they're successful in ultimately lowering the checkpoint inhibitor costs. Obviously they're motivated by market share, but there is an altruistic bent that will convince them to carry on and not get gobbled up by a big pharma firm.

  • @gz.degamfmmmgh-mjcggdds9ms914
    @gz.degamfmmmgh-mjcggdds9ms914 3 роки тому +3

    Thank You!

  • @neerajgene
    @neerajgene 2 роки тому

    Has been lagging quite poorly of late but hopefully once the company releases the entire data set with durability of response, this should see an uptick in share price!

  • @seanroberson9666
    @seanroberson9666 3 роки тому +5

    Long CKPT

  • @unknownperson-zz9kp
    @unknownperson-zz9kp 3 роки тому +2

    Interesting but when is data coming out

    • @breakingbiotech
      @breakingbiotech  3 роки тому +4

      Q4-2021 - Cosibelimab P3
      TBD - CK101 in NSCLC

  • @stevegreen5638
    @stevegreen5638 3 роки тому

    Thoughts on SQZ Biotech?

  • @gz.degamfmmmgh-mjcggdds9ms914
    @gz.degamfmmmgh-mjcggdds9ms914 3 роки тому +2

    ⭐⭐⭐⭐⭐